☆ 4.6 Editorial Material

Systemic treatment of metastatic hormone-sensitive prostate cancerdupfront triplet versus doublet combination therapy

ESMO OPEN (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial

Hannah L. Rush et al.

Summary: Patient-reported quality of life was better for patients receiving abiraterone acetate plus prednisone or prednisolone (AAP) alongside standard of care (SOC) compared to docetaxel plus SOC in locally advanced or metastatic hormone-sensitive prostate cancer, with particularly significant differences in the first year.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Matthew R. Smith et al.

Summary: Darolutamide, in combination with androgen-deprivation therapy and docetaxel, significantly increased overall survival among patients with metastatic hormone-sensitive prostate cancer compared to placebo plus androgen-deprivation therapy and docetaxel. The addition of darolutamide also led to improvement in secondary end points without notable differences in adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics

Philip Sutera et al.

Summary: Four different definitions of metastatic volume in mCSPC were compared with similar patient classifications, outcomes, and genetic makeup. High-volume disease was associated with worse overall survival, while low-volume disease with specific mutations may exhibit more aggressive clinical behavior. Incorporating tumor genetics may offer further refinement of current metastatic definitions.

PROSTATE CANCER AND PROSTATIC DISEASES (2022)

Add to Collection

Review Urology & Nephrology

The role of radiotherapy in oligometastatic hormone-sensitive prostate cancer

Hoda Abdel-Aty et al.

Summary: The role of radiotherapy in the management of oligometastatic hormone-sensitive prostate cancer (HSPC) has been reviewed. Studies have shown that prostate radiotherapy improves survival in newly diagnosed oligometastatic HSPC and is now recommended standard of care. Additionally, the use of stereotactic ablative radiotherapy for metastases-directed therapy has shown promising results in local control and survival advantage.

CURRENT OPINION IN UROLOGY (2022)

Add to Collection

Article Oncology

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Andrew J. Armstrong et al.

Summary: Clinical Trial Updates provide an opportunity to disseminate additional results from studies that have already reported their primary endpoint. This study demonstrates that enzalutamide plus androgen deprivation therapy significantly prolongs survival in patients with metastatic hormone-sensitive prostate cancer, and continues to improve other secondary endpoints.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design

Karim Fizazi et al.

Summary: Combining androgen deprivation therapy, docetaxel, and abiraterone in de novo metastatic castration-sensitive prostate cancer improved overall survival and radiographic progression-free survival with a modest increase in toxicity, mostly hypertension.

LANCET (2022)

Add to Collection

Article Medicine, General & Internal

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial

Chris Parker et al.

Summary: This study suggests that radiotherapy to the prostate can improve overall survival for patients with newly diagnosed prostate cancer and low metastatic burden, without affecting their quality of life. However, it does not provide the same benefit for patients with high metastatic burden.

PLOS MEDICINE (2022)

Add to Collection

Article Oncology

Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials

Matthew P. Deek et al.

Summary: This study presents the long-term outcomes of metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) and investigates the impact of high-risk mutations on treatment outcomes.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Oncology

Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis

B. A. Maiorano et al.

Summary: This study conducted a systematic review and meta-analysis to evaluate the effectiveness of combining androgen receptor targeted agents (ARTA) with docetaxel and androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) patients. The results showed that the triplet therapy significantly improved overall survival and progression-free survival compared to docetaxel plus ADT. The safety profile of the triplet therapy was comparable to that of docetaxel plus ADT, except for an increased risk of severe hypertension.

ESMO OPEN (2022)

Add to Collection

Article Urology & Nephrology

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited

Matthew P. Deek et al.

Summary: Somatic mutational profiles across the spectrum of metastatic castration-sensitive prostate cancer reveal associations between TP53 mutations and clinical outcomes in patients with oligometastasis, indicating a potential biological definition of oligometastasis beyond numerical classifications. Mutation analysis in TP53 and DNA double-strand break repair genes may help predict the number of metastases and clinical outcomes in patients with mCSPC.

EUROPEAN UROLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Medicine, General & Internal

Prostate cancer

Richard J. Rebello et al.

Summary: Prostate cancer is a prevalent disease among men, with key genetic alterations including gene fusions, oncogene amplification, and mutations in androgen receptors. Treatment options range from active surveillance to surgery and radiotherapy for localized disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

Add to Collection

Article Oncology

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Kim N. Chi et al.

Summary: The final analysis of the TITAN study confirmed that apalutamide plus ADT improved overall survival, delayed castration resistance, maintained health-related quality of life, and had consistent safety in a broad population of patients with mCSPC, despite crossover.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

Suzanne Carreira et al.

Summary: PARP inhibitors show varied effects in treating APCs with DNA repair defects. The greatest benefit is seen in patients with BRCA2 homozygous deletion, biallelic loss of PALB2, and loss of ATM protein expression. Loss of RAD51 foci, evaluating homologous recombination repair function, is predominantly found in tumors with biallelic BRCA1/2 and PALB2 alterations.

CANCER DISCOVERY (2021)

Add to Collection

Article Oncology

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

C. Parker et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Meeting Abstract Oncology

Abiraterone acetate plus prednisolone for hormone-naive prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476)

N. James et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Maha Hussain et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Abiraterone acetate plus prednisone in patients with newly Croatia& diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Karim Fizazi et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

Andrew J. Armstrong et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

N. W. Clarke et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

M. R. Sydes et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Christos E. Kyriakopoulos et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Endocrinology & Metabolism

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)

Edoardo Francini et al.

PROSTATE (2018)

Add to Collection

Article Oncology

Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis

Susan Feyerabend et al.

EUROPEAN JOURNAL OF CANCER (2018)

Add to Collection

Article Medicine, General & Internal

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Christopher C. Parker et al.

LANCET (2018)

Add to Collection

Article Medicine, General & Internal

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

N. D. James et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Multidisciplinary Sciences

Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories

Renea A. Taylor et al.

NATURE COMMUNICATIONS (2017)

Add to Collection

Article Urology & Nephrology

A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer

Hae Su Kim et al.

BMC UROLOGY (2017)

Add to Collection

Review Urology & Nephrology

Prostate cancer in men of African origin

Kathleen F. McGinley et al.

NATURE REVIEWS UROLOGY (2016)

Add to Collection

Article Urology & Nephrology

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

Gwenaelle Gravis et al.

EUROPEAN UROLOGY (2016)

Add to Collection

Article Oncology

Prostate cancer in the elderly

Emil Scosyrev et al.

CANCER (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.